V
Vladimir Tesar
Researcher at First Faculty of Medicine, Charles University in Prague
Publications - 307
Citations - 22066
Vladimir Tesar is an academic researcher from First Faculty of Medicine, Charles University in Prague. The author has contributed to research in topics: Medicine & Kidney disease. The author has an hindex of 48, co-authored 256 publications receiving 17061 citations. Previous affiliations of Vladimir Tesar include Charles University in Prague.
Papers
More filters
Geographic Differences in Genetic Susceptibility to IgA Nephropathy: GWAS Replication Study and Geospatial Risk Analysis
Krzysztof Kiryluk,Yifu Li,Simone Sanna-Cherchi,Simone Sanna-Cherchi,Mersedeh Rohanizadegan,Hitoshi Suzuki,Frank Eitner,Holly J. Snyder,Murim Choi,Ping Hou,Francesco Scolari,Claudia Izzi,Maddalena Gigante,Loreto Gesualdo,Silvana Savoldi,Antonio Amoroso,Daniele Cusi,Pasquale Zamboli,Bruce A. Julian,Jan Novak,Robert J. Wyatt,Robert J. Wyatt,Krzysztof Mucha,Markus Perola,Markus Perola,Markus Perola,Kati Kristiansson,Alexander Viktorin,Patrik K. E. Magnusson,Gudmar Thorleifsson,Gudmar Thorleifsson,Unnur Thorsteinsdottir,Unnur Thorsteinsdottir,Kari Stefansson,Kari Stefansson,Anne Boland,Marie Metzger,Lise Thibaudin,Christoph Wanner,Kitty J Jager,Shin Goto,Dita Maixnerova,Hussein H. Karnib,Judit Nagy,Ulf Panzer,Jingyuan Xie,Nan Chen,Vladimir Tesar,Ichiei Narita,François Berthoux,Juergen Floege,Bénédicte Stengel,Hong Zhang,Richard P. Lifton,Ali G. Gharavi +54 more
TL;DR: In this article, the authors localized five IgAN susceptibility loci on Chr.6p21 (HLA-DQB1/DRB1, PSMB9/TAP1, and DPA1/DPB2 loci), Chr.1q32 (CFHR3/R1 locus), and Chr.22q12 (HORMAD2 locus) and tested association of these loci in eight new independent cohorts of Asian, European, and African-American ancestry.
Journal ArticleDOI
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial
Rachel B Jones,Shunsuke Furuta,Jan Willem Cohen Tervaert,Thomas H. Hauser,Raashid Luqmani,Matthew D. Morgan,Chen Au Peh,Caroline O. S. Savage,Mårten Segelmark,Vladimir Tesar,Pieter van Paassen,Michael Walsh,Kerstin Westman,David Jayne +13 more
TL;DR: At 24 months, rates of the composite outcome of death, end-stage renal disease and relapse did not differ between groups and, in the rituximab group, B cell return was associated with relapse.
Journal ArticleDOI
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.
Brad H. Rovin,Sharon G. Adler,Jonathan Barratt,Frank Bridoux,Kelly A. Burdge,Tak Mao Chan,H. Terence Cook,Fernando C. Fervenza,Keisha L. Gibson,Richard J. Glassock,David Jayne,Vivekanand Jha,Adrian Liew,Zhihong Liu,Juan M. Mejia-Vilet,Carla M. Nester,Jai Radhakrishnan,Elizabeth M. Rave,Heather N. Reich,Pierre Ronco,Jan-Stephan F. Sanders,Sanjeev Sethi,Yusuke Suzuki,Sydney C.W. Tang,Vladimir Tesar,Marina Vivarelli,Jack F.M. Wetzels,Lyubov Lytvyn,Jonathan C. Craig,David J. Tunnicliffe,Martin Howell,Marcello Tonelli,Michael Cheung,Amy Earley,Jürgen Floege +34 more
TL;DR: The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Glomerular Diseases is an update to the KDIGO 2012 guideline.
Journal ArticleDOI
Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy
TL;DR: Assessment ofPLA2R antigen in biopsy specimens is more sensitive than the serological test for the diagnosis of PLA2R-related MN which can be established retrospectively in case of delayed serum sampling.
Journal ArticleDOI
Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study
Vladimir Tesar,Stéphan Troyanov,Shubha Bellur,Jacobien C. Verhave,H. Terence Cook,John Feehally,Ian S.D. Roberts,Daniel C. Cattran,Rosanna Coppo +8 more
TL;DR: Immunosuppression was associated with a significant reduction in proteinuria, a slower rate of renal function decline, and greater renal survival and CS reduced the risk of progression regardless of initial eGFR and in direct proportion to the extent of proteinuria in this cohort.